

The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books

Dec 14, 2020 • 58min
Ep83: David Lee on Impact in Pharmaceuticals
David Lee, CEO of Servier Pharma, on a nonprofit model.

Nov 23, 2020 • 59min
Ep82: Andrew Farnum on Medicines From Unusual Traits
Andrew Farnum, CEO of Variant Bio, on drug discovery based on rare genetic traits.

Nov 12, 2020 • 1h 7min
Ep81: Simba Gill on Microbiome Therapies
Simba Gill, CEO of Evelo Biosciences, on microbiome therapies.

Oct 28, 2020 • 52min
Ep80: Peter Kolchinsky on Pharma's Soul
Peter Kolchinsky of RA Capital on making drugs affordable, and keeping incentives for drug discovery.

Oct 26, 2020 • 1h 10min
Ep79: Daphne Koller on Machine Learning for Drug Discovery
Daphne Koller, CEO of insitro, on machine learning for drug discovery

Oct 13, 2020 • 1h 6min
Ep78: Pearl Huang on Exoneural Cancer Biology
Pearl Huang, CEO of Cygnal Therapeutics, on Exoneural Cancer Biology

Sep 29, 2020 • 1h 21min
Ep77: Jennifer Petter on Drugging RNA Targets
Jennifer Petter, CSO of Arrakis Therapeutics, on small molecule drugs for RNA targets

Sep 8, 2020 • 1h 9min
Ep76: Otello Stampacchia on Becoming a Biotech VC
Otello Stampacchia on becoming a biotech venture capitalist.

Aug 10, 2020 • 1h 4min
Ep75: Rosana Kapeller on Drugging the Repeatome
Rosana Kapeller, CEO of ROME Therapeutics

Jul 21, 2020 • 1h 16min
Ep74: Abe Ceesay's Path to Leadership
Abe Ceesay, CEO of Tiburio Therapeutics